Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1673 • ACR Convergence 2024
Assessing the Feasibility of a Mediterranean-Style Diet for Patients with Rheumatoid Arthritis in a Racially and Culturally Diverse Population Across the United States
Chelsea Thompson¹, iazsmin Ventura¹, Cuoghi Edens², Tamiko Katsumoto³ and Sowmya Popuri⁴, ¹Section of Rheumatology, University of Chicago, Chicago, IL, ²Section of Pediatric Rheumatology, Section of Rheumatology, University of Chicago, Chicago, IL, ³Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Section of Internal Medicine, Loyola Medicine MacNeal, Maywood, IL
Background/Purpose: In 2023, the American College of Rheumatology published a conditional recommendation for patients living with Rheumatoid Arthritis to follow a “Mediterranean style” diet. However,…
Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Parmita Das¹, Snehin Rajkumar², Eric Yen³ and Ram Singh⁴, ¹University of California Los Angeles, Saint Johns, ²UCLA David Geffen School of Medicine, Irvine, CA, ³UCLA, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…
Abstract Number: 1882 • ACR Convergence 2024
30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database
Shobhit Piplani¹, Priyanshu Jain², Vladimir Jelic³, Clement Tagoe⁴ and Beverly Johnson⁵, ¹Jacobi Medical Center/North Central Bronx Albert Einstein College of Medicine NYC Health and Hospitals, Bronx, NY, ²Jawaharlal Nehru Medical College, Belgaum, Karnataka, India, Bronx, NY, ³Jacobi Medical Center/North Central Bronx, Bronx, NY, ⁴Albert Einstein College of Medicine, FRESH MEADOWS, NY, ⁵Albert Einstein College of Medicine, New York, NY
Background/Purpose: Rheumatoid Arthirits (RA) is associated with heightened morbidity, diminished quality of life, and increased healthcare expenses. This research aims to bridge this gap by…
Abstract Number: 1968 • ACR Convergence 2024
Development and Validation of an Arthritis-Detection Algorithm Using Thermal Imaging in Adults and Children
Thomason Jenna¹, Sullivan Erin², Rajdeep Pooni³, Liau Adriel⁴, Sadie Van den Bogaerde⁵, Audrey Luey⁶, Iris Hamilton⁷, Sriya Paluvayi⁶, Megan Tran¹, Janeth Robles-Navarro¹, Ian Muse⁸, Ava Klein⁴, Tzielan Lee⁹, Grant Hughes⁵, Alison Bays⁵, Elizabeth Ferucci¹⁰, Debosmita Biswas¹¹, Savannah Patridge¹¹ and Yongdong (Dan) Zhao¹², ¹University of Washington, Division of Rheumatology, Seattle, WA, ²Biostatistics, Epidemiology, and Analytics in Research (BEAR) Core, Seattle Children’s Research Institute, Seattle, WA, ³Stanford University, Palo Alto, CA, ⁴Seattle Children’s Research Institute, University of Washington, Seattle, ⁵University of Washington, Seattle, WA, ⁶Seattle Children’s Research Institute, University of Washington, Seattle, WA, ⁷Seattle Children's Hospital, Seattle, ⁸Seattle Children's Research institute, Seattle, WA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Alaska Native Tribal Health Consortium, Anchorage, AK, ¹¹University of Washington, Department of Radiology, Seattle, WA, ¹²University of Washington, Redmond, WA
Background/Purpose: The Thermal imaging-based Temperature After Within-limb Calibration (TAWiC) algorithm for the detection of arthritis in the knees has been validated in children by our…
Abstract Number: 2210 • ACR Convergence 2024
Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality
Rebecca Brooks¹, Sara Achenbach², Vanessa Kronzer¹, Elena Myasoedova¹, Cynthia Crowson¹ and John Davis¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Both RF and anti-CCP are associated with erosive disease, increased disease activity, and adverse outcomes in RA. However, there have been limited studies investigating how…
Abstract Number: 2229 • ACR Convergence 2024
Aptamer Based Proteomic Profiling Demonstrates Significant Differences in Methotrexate Responders versus Non-responders in Newly Diagnosed Rheumatoid Arthritis and Adds Potential Value to Clinical Examination
Kaien Gu¹, Leanne Lac¹, Nathalie Carrier², Liam O'Neil¹, Gilles Boire³, Pingzhou Hu⁴ and Carol Hitchon¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴Western University, London, ON, Canada
Background/Purpose: Despite methotrexate (MTX) being the cornerstone of rheumatoid arthritis (RA) therapy, uncertainty exists around who will respond to MTX. We aimed to determine the…
Abstract Number: 2245 • ACR Convergence 2024
Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs
Chary Lopez-Pedrera¹, Laura Muñoz-Barrera², Rafaela Ortega-Castro³, Sagrario Corrales², Jerusalén Calvo⁴, Concepción Aranda-Valera⁵, María Lourdes Ladehesa-Pineda¹, Pilar Font², Ismael Sánchez Pareja², Elena Moreno-Caño⁵, María Carmen Ábalos-Aguilera⁶, Christian Merlo-Ruiz⁶, Mª Angeles Aguirre-Zamorano⁷, Tomás Cerdó², Nuria Barbarroja², Carlos Perez-Sanchez² and Alejandro Escudero-Contreras², ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain
Background/Purpose: The main objective of this study was to conduct extensive clinical and molecular analyses to accurately characterize the specific effects of Baricitinib (4 mg/day)…
Abstract Number: 2265 • ACR Convergence 2024
Patient’s Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁷ and Klaus Krüger⁹, ¹Dept of Immunology and Rheumatology, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Rheumatology, Tübingen, Germany, ⁴Hannover Medical School, Department for Rheumatology and Immunology, Herne, Germany, ⁵Knappschaftsklinikum Saar GmbH, Püttlingen, Germany, ⁶StatConsult GmbH, Statistics, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Immunology, Wiesbaden, Germany, ⁸AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, ⁹Rheumatologisches Praxiszentrum, Munich, Germany, München, Germany
Background/Purpose: Patient’s Global Assessment of disease activity (PtGA) was found to be the most relevant limiting factor for achieving Boolean 1.0 remission in patients with…
Abstract Number: 2283 • ACR Convergence 2024
Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry
Joshua Baker¹, Kristi Mizelle², Wassim Saikali³, Page Moore⁴, Hyung-Joo Kang⁴, David Gruben⁵, Ahmed Shelbaya⁶, Lori Stockert⁷ and Jacqueline O'Brien⁴, ¹Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ²TPMG Rheumatology, Newport News, VA, ³Rheumatology and Pulmonary Clinic, Beckley, WV, ⁴CorEvitas, LLC, Waltham, MA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Janus kinase inhibitors (JAKi) are a widely acceptable drug class in the treatment of RA. However, real-world data on the patterns of JAKi use and…
Abstract Number: 2589 • ACR Convergence 2024
A Nationwide Analysis of Risk of Acute Coronary Syndrome in RA Patients with Interstitial Lung Disease
Omair Khan¹, Azka Naeem², Kundan Jana², Syed Mujtaba Baqir², Tharun Shyam² and Saumya Nanda², ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY
Background/Purpose: Rheumatoid Arthritis (RA) and Interstitial Lung Disease (ILD) are systemic inflammatory conditions that independently increase the risk of Acute Coronary Syndrome (ACS). However, there…
Abstract Number: 2675 • ACR Convergence 2024
Which Arthralgia Patients at Risk for RA Benefited from Treatment with Methotrexate?; Results from the TREAT EARLIER Trial
Stijn Claassen¹, Quirine Dumoulin², Kasper Glas³, Esmeralda Molenaar⁴, Hanna van Steenbergen¹ and Annette van der Helm-van Mil⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³Reumazorg Zuid West Nederland, Goes, The Netherlands, Goes, Zeeland, Netherlands, ⁴Groene Hart Ziekenhuis, Gouda, The Netherlands, Gouda, Zuid-Holland, Netherlands, ⁵LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: A one-year methotrexate treatment in CSA has been shown to induce sustained reduction in subclinical inflammation during 2-years follow-up. We aim to study if…
Abstract Number: 0007 • ACR Convergence 2024
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Ryota Sato¹, Mitsuhiro Akiyama², Koichi Oshita³, Yuko Kawano³, Yuki Imura³, Piruzyan Mariam⁴, Manami Kikuchi³, Mikako Murase³, Sachiko Mochiduki³, Naohiro Hashimoto³, Masayuki Watanabe³, Keiko Yoshimoto⁵, Tsutomu Takeuchi⁶, Kenji Chiba⁷ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Brighton, MA, ²Keio University School of Medicine, Palo Alto, CA, ³Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ⁴Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
Abstract Number: 0046 • ACR Convergence 2024
Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies
Jeba Atkia Maisha¹, Alina Sememenko², Jun Kim², Mario Navarrete², XIAOBO MENG¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, Canada
Background/Purpose: Rheumatoid Arthritis (RA) begins after a prolonged preclinical phase which is marked by the development of RA antibodies, typically against citrullinated proteins (ACPA). The…
Abstract Number: 0064 • ACR Convergence 2024
Anti-Citrullinated Protein Antibodies Arise During Affinity Maturation of Germline-Encoded Antibodies to Carbamylated Proteins in Rheumatoid Arthritis
Marta Escarra-Senmarti¹, Michael Chungyoun², Dylan Ferris¹, Jeffrey Gray² and Felipe Andrade³, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²The Johns Hopkins Whiting School of Engineering, Baltimore, MD, ³The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The production of antibodies to modified self-antigens is a hallmark in rheumatoid arthritis (RA). Antibodies to citrullinated (ACPAs) and carbamylated proteins (CarP) are of…
Abstract Number: 0155 • ACR Convergence 2024
Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Fizza Zulfiqar¹, Morgan Steele², Sharanya Shre Ezhilarasan Santhi³, Bryanna Singh², Jaisal Brar³, Sumit Raut³, Prami Nakarmi³, Samhitha Bitla Reddy³, Ojo Ayomide³, Bashar Roumia³, Fariha Tareen³, Nathan Crook³, Vanessa Drust³, Ahmed Fawzy Mohamed³, Asad Mohammad Jani³, Jennifer Orejuela³, Siena Captain³, Nikhil Vojalla³, Muhammad Bilal⁴, Rida Fatima⁴, Sanjana Kesireddy³, Paige Misner³, Rishab Prabhu³, Camelia Arsene³, Jawad Bilal⁵ and Jacky Duong³, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²Trinity Health Oakland, Pontiac, MI, ³Trinity Health Oakland, Pontiac, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Southeast Tucson, Clinician Rheumatologist, Tuscon
Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].